Corsera Health
Corsera Health Raises $80M Series A | Once-Yearly Cardiovascular RNAi
Corsera Health Closes $80M Series A
Corsera Health, developing once-yearly RNAi treatments for cardiovascular diseases, has raised $80 million in Series A funding.
Key Highlights
- Novel once-yearly dosing approach
- Focus on cardiovascular diseases
- RNAi therapeutic platform
Company Overview
Corsera Health is developing RNA interference therapeutics that require only once-yearly dosing, potentially transforming treatment adherence for chronic cardiovascular conditions.
Company Info
Investors (2)
Share
Related Reports
Armadin Raises $255.5M Series B for Autonomous Security
Armadin raised a $255.5 million Series B co-led by Andreessen Horowitz and Accel to scale its agentic security platform and its research, training, and go-to-market efforts.
Homeward Raises $120M Series D for Cash Offer and Bridge Financing
Homeward raised a $120 million Series D led by Saluda Grade, plus $330 million in asset-backed debt, to expand cash offer and bridge financing for real estate agents.
Varda Raises $251M Series D for Space-Based Pharmaceutical Processing
Varda Space Industries raised a $251 million Series D led by Lux Capital and Natural Capital to scale space-based pharmaceutical processing.
Turn your sales ideas into reality today
Start your 14-day Pro trial today. No credit card required.
Start building for free